Correlation Between Rani Therapeutics and Skye Bioscience,

Can any of the company-specific risk be diversified away by investing in both Rani Therapeutics and Skye Bioscience, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Rani Therapeutics and Skye Bioscience, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Rani Therapeutics Holdings and Skye Bioscience, Common, you can compare the effects of market volatilities on Rani Therapeutics and Skye Bioscience, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Rani Therapeutics with a short position of Skye Bioscience,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Rani Therapeutics and Skye Bioscience,.

Diversification Opportunities for Rani Therapeutics and Skye Bioscience,

0.61

Correlation Coefficient

Rani Therapeutics  Skye Bioscience,

Poor diversification

The 3 months correlation between Rani and Skye is 0.61. Overlapping area represents the amount of risk that can be diversified away by holding Rani Therapeutics Holdings and Skye Bioscience, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Skye Bioscience, Common and Rani Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Rani Therapeutics Holdings are associated (or correlated) with Skye Bioscience,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Skye Bioscience, Common has no effect on the direction of Rani Therapeutics i.e., Rani Therapeutics and Skye Bioscience, go up and down completely randomly.

Pair Corralation between Rani Therapeutics and Skye Bioscience,

Given the investment horizon of 90 days Rani Therapeutics Holdings is expected to under-perform the Skye Bioscience,. But the stock apears to be less risky and, when comparing its historical volatility, Rani Therapeutics Holdings is 1.32 times less risky than Skye Bioscience,. The stock trades about -0.47 of its potential returns per unit of risk. The Skye Bioscience, Common is currently generating about -0.34 of returns per unit of risk over similar time horizon. If you would invest  428.00  in Skye Bioscience, Common on September 21, 2024 and sell it today you would lose (142.00) from holding Skye Bioscience, Common or give up 33.18% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Rani Therapeutics Holdings  vs.  Skye Bioscience, Common

Rani Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Rani Therapeutics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

Skye Bioscience, Common

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Skye Bioscience, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.

Pair Trading with Rani Therapeutics and Skye Bioscience,

The main advantage of trading using opposite Rani Therapeutics and Skye Bioscience, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Rani Therapeutics position performs unexpectedly, Skye Bioscience, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Skye Bioscience, will offset losses from the drop in Skye Bioscience,'s long position.

The idea behind Rani Therapeutics Holdings and Skye Bioscience, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.